Skip to search formSkip to main contentSkip to account menu

CU201

Known as: B9870 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Oligopeptides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Antagonist, partial agonist and antiproliferative actions of B‐9870 (CU201) as a function of the expression and density of the bradykinin B1 and B2 receptors
A bradykinin (BK) B2 receptor (B2R) antagonist, B‐9870 (CU201), has been proposed to behave as a ‘biased agonist’ at B2Rs and to… 
2006
2006
A preclinical pharmacodynamic analysis of CU201, a novel bradykinin antagonist, using a calcium flux assay in lung cancer cell lines
A105 Background: Neuroendocrine features, including paracrine and autocrine growth stimulation by various neuropeptides, are… 
2005
2005
Prostaglandin E2 and Bradykinin contribute to head and neck squamous cell carcinoma carcinogenesis via EGFR dependent and independent mechanisms.
169 The epidermal growth factor receptor (EGFR) is upregulated in majority of head and neck squamous cell carcinoma (HNSCC) cell… 
Highly Cited
2002
Highly Cited
2002
Bradykinin-related compounds as new drugs for cancer and inflammation.
Bradykinin (BK) (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) is an important growth factor for small-cell lung cancer (SCLC) and… 
2002
2002
Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.
Small cell lung cancers (SCLCs), many non-SCLCs, and other cancers have neuroendocrine features, including paracrineand autocrine… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)